Electroconvulsive therapy (ECT) is a long-standing treatment modality with demonstrated efficacy in addressing severe psychiatric illnesses, including major depressive disorder, bipolar disorder, schizophrenia, and psychotic depression. Unlike antidepressant medications, ECT is characterized by an acute time course of response, though benefits can deteriorate over time and carry a significant side effect profile, including memory impairment. This session will review the state-of-the-art in terms of electroconvulsive therapy for psychiatric disease and explore emerging research.
Ketamine has recently attained FDA approval for the treatment of major depressive disorder that is refractory to other therapies. Unlike other medical antidepressant interventions, its effects are immediate and are being integrated into the therapeutic approach to acutely suicidal and destabilized patients. However, serious limitations to its therapeutic potential exist in the transient temporal profile of response, as well as in the potential for abuse. This session will also explore the role of Ketamine in the treatment of refractory psychiatric illness and the mechanistic implications of Ketamine therapy on our understanding of disease pathophysiology.
- Summarize the use of modern applications of ECT therapy.
- Explain neuroimaging biomarkers that can predict treatment response to ECT.
- Identify recent advances in the use of intravenous and intranasal Ketamine for treatment-refractory depression.
- Discuss how advances in neurobiology and pharmacology have led to novel treatments for treatment-resistant depression.
Structural Plasticity of the Hippocampus and Amygdala Induced by Electroconvulsive Therapy in Major Depression
Amber M Leaver, PhD
Modern Applications: Unilateral Ultra-Brief Pulse ECT
Gregory Sahlem, MD
Pharmacological Mechanisms of Action of Ketamine and Therapeutic Considerations
Asim A Shah, MD
The Role of Ketamine in the Treatment-Resistant Depression Clinic
Patricio Riva Posse, MD